Many Greenlanders Face 10 Times Higher Risk of Diabetes – Exercise May Be Their Only Solution

While diabetes was virtually unknown in Greenland in the 1960s, its current prevalence there is now nearly twice as high as in Denmark. One group of Greenlanders faces a significantly higher risk of developing the chronic disease. Specifically, this at risk group is made up of four percent of Greenland’s Inuit population, as revealed by a population study ten years ago.

"These four percent carry a specific mutation in the TBC1D4 gene, which gives them a tenfold increased risk of type 2 diabetes. The gene variant makes them highly glucose intolerant – meaning that when they consume sugar, they struggle to get it out of their bloodstream," explains Professor Jørgen Wojtaszewski of the University of Copenhagen’s Department of Nutrition, Exercise and Sports.

Professor Wojtaszewski and a research team led by the University of Copenhagen and the Steno Diabetes Center Greenland have now investigated how exactly the gene variant affects the body. Their studies were conducted on a group of Greenlandic carriers of the variant, with the results now published in Nature Metabolism.

"We can see that people with this genentic variant have insulin-resistant musculature. This means that their muscle tissue responds poorly to insulin, which is critical, as muscles account for the majority of the body's sugar uptake. Consequently, this condition dramatically increases their risk of developing type 2 diabetes," says Wojtaszewski, adding: 

"What’s particularly unique is that insulin resistance is typically present not just in muscles, but in the liver, fat tissue, and other organs and cells as well. But for carriers of this gene variant, resistance is found only in the muscles, which is unprecedented."

This also means that carriers of the variant do not become ‘ill’, as long as their pancreas can effectively release insulin, and their other organs maintain normal insulin sensitivity.

"Unlike other pre-diabetic conditions, these individuals do not exhibit elevated fasting blood sugar or insulin levels, nor indicators of heightened long-term blood sugar. And this makes it all the more challenging for doctors to detect," explains Wojtaszewski.

An Hour of Daily Exercise Helps

At the molecular level, the gene variant prevents carriers from expressing the TBC1D4 protein in their muscle tissue. As part of the study, researchers tested whether physical activity could increase insulin sensitivity in the muscles of this segment of the Greenlandic population. Previous studies in animal models had indicated that the presence of TBC1D4 is crucial for this to happen. The hypothesis was that exercise might not work for this specific group.

"It turns out that even a single training session involving one hour of moderate physical activity increases insulin sensitivity in the muscles of gene variant carriers – although the effect is not as pronounced as in non-carriers. This strongly suggests that muscle use through physical activity can reduce the risk of type 2 diabetes in gene variant carriers," says Jørgen Wojtaszewski, adding:

"People with this gene variant have constituted a relatively large part of the population for hundreds of years, and they will continue to for generations to come. Now we can advise them on how to prevent diabetes – namely through physical activity."

 Unfortunately, current diabetes medications are not suitable for this group, as the professor explains:

"The challenge with treating carriers using conventional diabetes medications is that these drugs do not increase insulin sensitivity in muscle, but primarily serve to reduce sugar production in the liver, which subsequently lower overall blood sugar levels. However, since carriers of the variant do not have elevated blood sugar levels when not eating, such treatment carries a significant risk of causing dangerously low blood sugar."

Paving the Way for New Medications

Previous population studies in Greenland have provided insight into the genetic composition of less than 10% of the population. As such, a great deal of work lies ahead before genetic information can be made available for the entire population. Such information will be able to help personalize advice for individual gene variant carriers.

"However, the insight we’ve gained into human biology by combining data from these population studies with our follow-up physiological research is truly remarkable. This new understanding offers hope that, in the future, we may see a new type of medication for 'ordinary' type 2 diabetes," says Jørgen Wojtaszewski.

Because, even though the TBC1D4 protein is normally expressed in people with type 2 diabetes who don’t carry the gene variant, the regulation of its activity is impaired.

"We know that a particular enzyme, one activated during physical activity, positively influences TBC1D4 activity. The pharmaceutical industry is already working to identify molecules that can activate this enzyme to regulate TBC1D4 activity, and in doing so, enhance insulin sensitivity. If such a drug reaches the market, it could benefit most other forms of type 2 diabetes," concludes Jørgen Wojtaszewski.